In vitro sensitivity of human parainfluenza 3 clinical isolates to ribavirin, favipiravir and zanamivir

Human parainfluenza viruses (HPIV) are a prominent cause of both upper (URTI) and lower (LRTI) respiratory tract infection with a broad spectrum of presentation [1 –4]. HPIV3 is recognised as a cause of serious morbidity and mortality in the immunocompromised, in particular among haematopoietic stem cell transplant (HSCT) patients [3,5,6]. Immunity to HPIV3 is incomplete and re-infections occur throughout life. Currently there is no vaccine and no approved t reatment for HPIV3, indicating a clear and urgent need for a potential therapeutic candidate.
Source: Journal of Clinical Virology - Category: Virology Authors: Source Type: research